Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Celgene to promote Alkeran

  • News

Executive Summary

Celgene will distribute and promote GSK's oncologic agent Alkeran (melphalan) under Celgene label. Alkeran, approved for palliative treatment of multiple myeloma, had sales of about $15 mil. in 2002, Celgene said...

You may also be interested in...



New UK Biosimilars Pathway Suffers Setback

The UK’s implementation of a new national pathway for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as a cause of an indefinite delay in the consultation process.

Hikma Suspends Roll-Out Of Advair Rival

Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.

QUOTED. 18 January 2021. Chad Reynolds.

Chad Reynolds of RMQ+ spoke to Medtech Insight about practical strategies for managing economic operators efficiently and with a view to long-term compliance.

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By